Early actions by the new administration signal major changes in health policy, taxes, and pharmaceutical pricing.

Combining immunotherapy with chemotherapy shows promise in enhancing survival rates for extensive-stage small cell lung ...

With artificial intelligence (AI) capabilities freeing up workers and driving billions in gains, pharmacy may soon see a 75% ...

Raymond Osarogiagbon, MD, discusses the challenges of implementing lung cancer screening guidelines and the need for increased awareness and access.

Medicaid beneficiaries face higher rates of pulmonary hypertension, with significant economic burdens and racial disparities in prevalence and costs.

From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ...

Managed care will continue to evolve and employers and policy makers have a responsibility to understand how to best serve ...

Panelists discuss how novel targeted therapies for immunoglobulin A (IgA) nephropathy are transforming treatment paradigms by ...

Smoking prevalence is projected to decline by 2035, yet health consequences persist due to slower reductions among older ...

Kimlin Tam Ashing, PhD, of City of Hope National Medical Center, emphasizes the vital role of community engagement in cancer research, enhancing trust and communication between scientists and ...

Zongertinib shows promise for treating HER2-mutant non–small cell lung cancer (NSCLC), with significant activity against brain metastases and low interstitial lung disease risk, explains John Heymach, ...

The session follows the American Association for Cancer Research's prior call to action against executive orders that would ...